Cita APA

Heymach, J., Hanrahan, E., Mann, H., Langmuir, P., Natale, R., Johnson, B., . . . Ryan, A. (2008). Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.

Citación estilo Chicago

Heymach, J., E. Hanrahan, H. Mann, P. Langmuir, R. Natale, B. Johnson, R. Herbst, and A. Ryan. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.

Cita MLA

Heymach, J., et al. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.